Celfex AB enters sub-license agreement with MHG
Celfex AB has entered into a sub-license agreement with MHG Management GmbH for the development and commercialization of topical Fexofenadine for Atopic Dermatitis. This agreement secures Celfex's rights to the intellectual property portfolio covering the novel topical application of Fexofenadine.
The sub-license provides Celfex with the exclusive rights to develop, manufacture, and commercialize topical Fexofenadine products for dermatological indications. MHG Management GmbH, as the parent company of Celfex, will continue to provide strategic support and resources.
This agreement represents a key step in Celfex's strategy to bring innovative dermatology solutions to patients suffering from Atopic Dermatitis worldwide.
The information in this article is for informational purposes only and does not constitute medical advice. Celfex products are under clinical development and not yet approved for commercial use.